A recent survey of Biomedical company CEOs completed by the CHI-California Healthcare Institute, BayBio, and PWC in the US showed that access to capital, a burdensome and uncertain regulatory environment, and lack of innovation and productivity in research and development are the biggest threats to the biomedical industry’s growth over the next five years. In the survey, 74% of CEOs surveyed said their companies have delayed a research or development project in the past year, and 80% agreed that the current FDA regulatory approval process has slowed the growth of their organization. To see what else the CEO’s surveyed had to say, click the link here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.